The Creating Hope Act of 2011 would encourage the creation of new drugs for underserved children who suffer from serious and rare medical conditions, including life-threatening cancers, by providing a voucher to pharmaceutical companies who develop such drugs. This voucher could be used to

Pediatric Cancer Each year around 13,500 children are diagnosed with cancer in the US, that’s more than a classroom of kids a day.

35,000 children are currently in treatment for cancer.

Some 25% of all kids who are diagnosed with cancer die.

Some pediatric brain tumors, such as brain stem gliomas and pontine gliomas, are terminal upon diagnosis and no new protocols have been developed in 30 years.

The Creating Hope Act of 2011 provides market incentives to pharmaceutical companies to develop drugs for pediatric rare diseases.

PEDIATRIC CANCER Two weeks after Kids v Cancer Founder Nancy Goodman’s eight year old son, Jacob, was diagnosed with medulloblastoma, a rare form of pediatric brain cancer, doctors gave him a round of chemotherapy. Jacob’s tumors did not respond. Why then, didn’t Jacob’s medical team change his chemotherapy protocol? Because in the last 30 years, no new drugs have been developed to treat Jacob’s form of cancer. In fact, in the past 20 years, only one drug has been expressly developed for any form of pediatric cancer. Jacob died on January 16, 2009 when he was ten years old. http://wp.me/1cg8a

Onko-Sure® can be a valuable diagnostic tool in the worldwide battle against cancer, the second leading cause of death worldwide. Our Onko-Sure® in vitro diagnostic test enables physicians and their patients to effectively monitor and/or detect cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP). Onko-Sure® is a simple, non-invasive blood test used for the detection and/or monitoring of 14 different types of cancer including: lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, and pancreatic.
RXPC Onko-Sure Get Your Rear in Gear Colorectal Cancer Grassroots Effort http://bit.ly/ojAquc #Cancer #Health #RXPC #OnkoSure #investing

… The U.S. National Cancer Institute’s Gynecologic Oncology Group has conducted 16 clinical trials in over 500 patients using various therapeutic regimens in this patient population and found the most effective regimen tested resulted in a median survival of approximately 6 months and a 1 year survival of 5%. By contrast, in a phase 1 study not designed to show efficacy, ADXS11-001 demonstrate a median survival of 347 days and a one year survival of 53%. …